Senti Biosciences Holdings, Inc.
A biotech company that builds cells engineered with "gene circuits" — biological software programmed in so the cells can sense, compute, and respond much like a computer. Its therapies target hard-to-treat cancers, and the engineered cells are designed to attack tumors while sparing healthy tissue. Founded in 2016 by synthetic-biology pioneers, the name "Senti" comes from the cells' ability to "sense" their environment.
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lu Timothy KCEO, Director · 2 transactions | -10.2% | 745.3K | — | — | — |
| Rajangam KanyaPres. & Chief Med. & Dev. Off. · 2 transactions | -10.1% | 107.8K | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.